Charles Schwab Investment Management Inc Cytokinetics Inc Transaction History

Charles Schwab Investment Management Inc

  • $519 Billion
  • Q2 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 925,682 shares of CYTK stock, worth $48.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
925,682
Previous 775,556 19.36%
Holding current value
$48.5 Million
Previous $54.4 Million 7.76%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024
BUY
$47.86 - $75.05 $7.19 Million - $11.3 Million
150,126 Added 19.36%
925,682 $50.2 Million
Q1 2024

May 08, 2024
SELL
$63.75 - $108.06 $918,828 - $1.56 Million
-14,413 Reduced 1.82%
775,556 $54.4 Million
Q4 2023

Feb 06, 2024
BUY
$26.88 - $83.49 $893,948 - $2.78 Million
33,257 Added 4.39%
789,969 $66 Million
Q3 2023

Nov 08, 2023
SELL
$29.46 - $36.61 $423,222 - $525,939
-14,366 Reduced 1.86%
756,712 $22.3 Million
Q2 2023

Aug 09, 2023
BUY
$32.62 - $40.75 $1.58 Million - $1.97 Million
48,397 Added 6.7%
771,078 $25.2 Million
Q1 2023

May 11, 2023
SELL
$33.36 - $45.71 $113,457 - $155,459
-3,401 Reduced 0.47%
722,681 $25.4 Million
Q4 2022

Feb 13, 2023
BUY
$35.77 - $51.11 $746,519 - $1.07 Million
20,870 Added 2.96%
726,082 $33.3 Million
Q3 2022

Nov 14, 2022
BUY
$38.54 - $54.52 $3.79 Million - $5.35 Million
98,217 Added 16.18%
705,212 $34.2 Million
Q2 2022

Aug 15, 2022
BUY
$33.93 - $48.92 $220,646 - $318,126
6,503 Added 1.08%
606,995 $23.8 Million
Q1 2022

May 13, 2022
BUY
$29.74 - $46.0 $470,665 - $727,996
15,826 Added 2.71%
600,492 $22.1 Million
Q4 2021

Feb 11, 2022
SELL
$34.35 - $46.38 $922,881 - $1.25 Million
-26,867 Reduced 4.39%
584,666 $26.6 Million
Q3 2021

Nov 16, 2021
BUY
$18.54 - $35.74 $1.86 Million - $3.58 Million
100,229 Added 19.6%
611,533 $21.9 Million
Q2 2021

Aug 16, 2021
BUY
$19.79 - $26.99 $747,765 - $1.02 Million
37,785 Added 7.98%
511,304 $10.1 Million
Q1 2021

May 17, 2021
BUY
$18.57 - $25.68 $284,808 - $393,854
15,337 Added 3.35%
473,519 $11 Million
Q4 2020

Feb 16, 2021
BUY
$15.26 - $28.61 $142,391 - $266,959
9,331 Added 2.08%
458,182 $9.52 Million
Q3 2020

Nov 13, 2020
BUY
$20.58 - $28.96 $1.23 Million - $1.74 Million
59,962 Added 15.42%
448,851 $9.72 Million
Q2 2020

Aug 14, 2020
BUY
$11.15 - $24.64 $238,097 - $526,162
21,354 Added 5.81%
388,889 $9.17 Million
Q1 2020

May 15, 2020
BUY
$8.75 - $16.3 $78,863 - $146,911
9,013 Added 2.51%
367,535 $4.33 Million
Q4 2019

Feb 07, 2020
BUY
$7.95 - $11.84 $51,682 - $76,971
6,501 Added 1.85%
358,522 $3.8 Million
Q3 2019

Nov 08, 2019
BUY
$10.82 - $14.25 $240,160 - $316,293
22,196 Added 6.73%
352,021 $4.01 Million
Q2 2019

Aug 09, 2019
BUY
$7.95 - $11.25 $306,917 - $434,317
38,606 Added 13.26%
329,825 $3.71 Million
Q1 2019

May 14, 2019
BUY
$5.95 - $10.19 $38,460 - $65,868
6,464 Added 2.27%
291,219 $2.36 Million
Q4 2018

Feb 14, 2019
SELL
$5.91 - $9.29 $33,917 - $53,315
-5,739 Reduced 1.98%
284,755 $1.8 Million
Q3 2018

Nov 13, 2018
BUY
$6.4 - $9.85 $247,609 - $381,086
38,689 Added 15.36%
290,494 $2.86 Million
Q2 2018

Aug 08, 2018
BUY
$6.9 - $9.9 $178,109 - $255,548
25,813 Added 11.42%
251,805 $2.09 Million
Q1 2018

May 07, 2018
SELL
$7.2 - $10.05 $142,567 - $199,000
-19,801 Reduced 8.06%
225,992 $1.63 Million
Q4 2017

Jan 17, 2018
SELL
$7.25 - $15.65 $417,266 - $900,720
-57,554 Reduced 18.97%
245,793 $2 Million
Q3 2017

Nov 13, 2017
BUY
$12.0 - $15.0 $3.64 Million - $4.55 Million
303,347
303,347 $4.4 Million

Others Institutions Holding CYTK

# of Institutions
406
Shares Held
126M
Call Options Held
3.29M
Put Options Held
2.01M
View Full List

About CYTOKINETICS INC

CYTK Quotes by TradingView
  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.93B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email